TSL2109 not checked

Tasly · DYRK2-CDK4/6

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Dosage and Administration: Oral administration on an empty stomach, once daily. Applicable to 50mg (2 capsules of 25mg), 100mg (1 capsule of 100mg), 200mg (2 capsules of 100mg), 300mg (3 capsules of 100mg), 400mg (4 capsules of 100mg), and 500mg (5 capsules of 100mg) dose groups. Duration of Treatment: Multiple dosing, with each treatment cycle consisting of 28 days.”In the company’s words, NCT07514065 on ClinicalTrials.gov
Tested for
Metastatic Castration-Resistant Prostate Cancer Patients
Main trialPhase 1
“TSL2109 is a novel CDK4/6-DYRK2 dual-target inhibitor developed by Jiangsu Tasly Diyee Pharmaceutical Co., Ltd. for solid tumor treatment. Preclinical studies confirm its selective targeting of CDK4/6 and DYRK2, a eukaryotic CMGC family kinase. In palbociclib-resistant cell lines, TSL2109 downregulates cell cycle-related proteins and DYRK2 pathway ribosomal synthesis regulators (RRS1, CDK2), and upregulates p53, thus exerting synergistic antitumor effects and overcoming resistance to enzalutamide and palbociclib. As a small-molecule inhibitor with novel targets, structure and mechanism,…”In the company’s words, NCT07514065 on ClinicalTrials.gov
Other names
DYRK2-CDK4/6

Other drugs for Metastatic Castration-Resistant Prostate Cancer Patients

All 194 drugs for Metastatic Castration-Resistant Prostate Cancer Patients

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 31 Dec 2026 TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TSL2109

Following is part of Solo: you see every change to TSL2109 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in